News for Nektar Therapeutics (NKTR)

Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Qualit

PR NewswireSAN FRANCISCO, Feb. 26, 2025 SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com

PR NewswireSAN FRANCISCO and NEW YORK, Feb. 24, 2025 -- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study --SAN FRANCISCO and N

On December 31, 2024, Samlyn Capital, LLC executed a notable transaction by acquiring an additional 467,097 shares of Nektar Therapeutics at a trade price of $0

Eventide Asset Management, LLC, a well-regarded investment firm, recently made a significant adjustment to its holdings in Nektar Therapeutics. On December 31,

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving Nektar Therapeutics (NKTR), reducing its holdings

PR NewswireSAN FRANCISCO, Feb. 10, 2025 SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food

Nektar Therapeutics (NKTR) Monday said that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for its drug candidate rezpegaldesleukin for the treatment of atopic dermatitis in patients aged 12 years and older.

Nektar Therapeutics (NKTR) experienced a significant stock price drop of 5.02%, trading at $0.666 per share with a trading volume of 1.89413 million shares. The

PR NewswireSAN FRANCISCO, Jan. 10, 2025 SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com

”“ Vepdegestrant to be combined with Pfizer's novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a se

**media[511554]**

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media.

Summary Septerna Inc (SEPN), a clinical-stage biotechnology company based in South San Francisco, announced on January 6, 2025, the appointment of Gil Labrucher

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. ( SEPN), a clinical-stage biotech company pioneering a new era of G protein-coup

Nektar Therapeutics chief legal officer sells shares worth $44,800

Nektar Therapeutics CEO Robin Howard sells $131,649 in stock

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeti

Nektar Therapeutics chief legal officer sells $6,471 in stock